Updates

Date: 10th July, 2026 To, To, The Manager, The Manager, Department of Corporate Services, Listing Department, BSE Limited National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, ‘Exchange Plaza’, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 533573 NSE Symbol: APLLTD Dear Sir/Madam, Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Pursuant to Regulations 30 of the SEBI Listing Regulations we wish to inform you that in compliance with Regulation 36(1)(b) of the SEBI Listing Regulations, please find enclosed herewith the specimen letter sent to those Shareholders whose e-mail addresses are not registered with Company/Registrar & Transfer Agent/Depository Participants, providing the weblink of Company’s website along with the exact path from where the Annual Report for FY 2025-26 can be accessed as under: Annual-Report-2025-2026 Further, the Annual Report is also available on the website of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com. We request you to kindly take the same on record. Thanking you, Yours faithfully, For Alembic Pharmaceuticals Limited Manisha Saraf Company Secretary Encl.: A/a. ALEMBIC PHARMACEUTICALS LIMITED REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. ● TEL: (0265) 2280550, 2280880 ● FAX: (0265) 2281229 Website : www.alembicpharmaceuticals.com ● E-mail : alembic@alembic.co.in ● CIN : L24230GJ2010PLC061123 Alembic Pharmaceuticals Limited CIN: L24230GJ2010PLC061123 Registered Office: Alembic Road, Vadodara - 390 003, Tel: +91 265 6637000 Website: www.alembicpharmaceuticals.com | E-mail: apl.investors@alembic.co.in Ref. No.: Date : 10/07/2026 Name & Address of shareholder Folio No./DP-CLID : Dear Shareholder(s) / Sir / Madam, Sub: Notice of 16th Annual General Meeting of the Members of Alembic Pharmaceuticals Limited and Annual Report for Financial Year 2025-26 We are pleased to inform you that the 16th Annual General Meeting (‘AGM’) of Alembic Pharmaceuticals Limited (‘the Company’) is scheduled to be held on Wednesday, 5th August, 2026, at 4:00 p.m. (IST) through Video Conference facility/ Other Audio Visual Means (‘VC’/ ‘OAVM’). In compliance with Regulation 36(1)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (‘SEBI Listing Regulations, 2015’) soft copies of the Notice convening the AGM along with Annual Report for Financial Year 2025-26 is being sent through email to all those shareholder(s) whose e-mail address are registered with the Company Depository Participant(s). It came to our notice that no e-mail address is registered against your demat account / Folio number. Hence, in compliance with Regulation 36(1)(b) of the SEBI Listing Regulations, 2015, this letter is sent by the Company to inform you that the Annual Report can be accessed on the Company’s website at the weblink: https://alembicpharmaceuticals.com/annual-reports. Further, the exact path to access the Annual Report on the Company’s website i.e https://alembicpharmaceuticals.com/ is as under: Home > Investors > Financial Information > Annual Report >Annual Report 2025-26 The Notice of the AGM and the Annual Report are also available on the website of NSDL at www.evoting.nsdl.com and the stock exchanges on which the securities of the Company are listed, i.e., BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com, respectively. Key details for the AGM are as under: Sr. No. Particulars Dates 1. Last date for submission of TDS exemption forms 29th July, 2026 2. Record date for Final Dividend 29th July, 2026 3. Cut-off date for e-Voting 29th July, 2026 4. e-Voting start date and time Sunday, 2nd August, 2026 from 9:00 a.m. (IST) 5. e-Voting end date and time Tuesday, 4th August, 2026 at 5:00 p.m. (IST) 6. Dividend payment date On or from 6th August, 2026 In case, your KYC details are not yet registered pertaining to the name, postal address, E-mail address, telephone/mobile numbers, Permanent Account Number (PAN), nominations, power of attorney, bank details such as name of the bank and branch details, bank account number, MICR code, IFSC code, etc: i) In case shares are held in physical mode, members are requested to submit their service requests in the form(s) prescribed under SEBI Master Circular No. HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 dated 6th February, 2026 read with Master Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/91 dated 23rd June, 2025. The form(s) are available on the website of the Company at https://www.alembicpharmaceuticals.com/investor-related-forms/ and on the website of Company’s Registrar & Share Transfer Agent, MUFG Intime India Pvt. Ltd. (“MIIPL”) at https://web.in.mpms.mufg.com/KYC-downloads.html. ii) In case shares are held in electronic mode, members are requested to update the details with their respective Depository Participants. Should you have any queries or need any information/clarification, please write to or contact our RTA, M/s. MUFG Intime India Private Limited at “Geetakunj”, 1 Bhakti Nagar Society, Behind ABS Tower, Old Padra Road, Vadodara – 390015, Tel : +91 265 3566768, E-mail Id: investor.helpdesk@in.mpms.mufg.com. Thanking You, For Alembic Pharmaceuticals Limited Manisha Saraf Company Secretary